background
infect
control
measur
play
major
role
limit
humancameltohuman
transmiss
middl
east
respiratori
syndrom
coronaviru
merscov
howev
develop
effect
safe
human
camel
vaccin
warrant
method
extend
optim
previou
recombin
adenoviru
base
vaccin
platform
character
vivo
amplifi
specif
respons
gener
merscov
subunitbas
vaccin
gener
construct
express
fusion
protein
untarget
green
fluoresc
protein
evalu
efficaci
safeti
human
dipeptidyl
peptidas
transgen
tg
mice
result
immun
tg
mice
singl
dose
elicit
robust
signific
specif
immunoglobulin
g
neutral
antibodi
induc
dose
merscov
challeng
vaccin
confer
complet
protect
morbid
mortal
evidenc
significantli
undetectablereduc
pulmonari
viral
load
compar
control
group
howev
mice
exhibit
mark
pulmonari
perivascular
hemorrhag
postmerscov
challeng
despit
observ
protect
conclus
incorpor
merscov
vaccin
target
molecul
molecular
adjuv
enhanc
immunogen
efficaci
also
prevent
inadvert
pulmonari
patholog
viral
challeng
therebi
offer
promis
strategi
enhanc
safeti
potenc
vaccin
middl
east
respiratori
syndrom
coronaviru
merscov
novel
zoonot
viru
first
isol
fatal
human
case
saudi
arabia
viru
caus
sever
acut
fatal
respiratori
symptom
associ
system
infect
occasion
multiorgan
failur
octob
merscov
caus
laboratoryconfirm
infect
approxim
mortal
rate
countri
saudi
arabia
affect
countri
global
case
link
arabian
peninsula
merscov
continu
endem
year
potenti
spread
global
seen
outbreak
south
korea
spike
glycoprotein
merscov
aa
type
trimer
membran
protein
express
viru
surfac
bind
dipeptidyl
peptidas
target
cell
compris
ntermin
globular
subunit
aa
contain
receptorbind
domain
rbd
membraneproxim
subunit
aa
consist
transmembran
domain
intracellular
cytoplasm
domain
cd
involv
viral
fusion
target
cell
given
critic
role
viral
replic
protein
focu
merscov
vaccin
develop
similar
sever
acut
respiratori
syndrom
coronaviru
sarscov
main
target
vaccin
led
robust
induct
neutral
antibodi
nab
mediat
protect
immun
anim
sever
vaccin
candid
base
fulllength
truncat
protein
includ
vector
dna
nanoparticl
vaccin
well
rbd
proteinbas
subunit
vaccin
develop
investig
anim
model
although
candid
induc
high
level
nab
vaccin
anim
enter
phase
clinic
trial
candid
associ
low
immunogen
requir
multipl
dose
importantli
vaccin
research
member
coronavirus
includ
sarscov
reveal
sever
safeti
concern
associ
use
sbase
vaccin
includ
inflammatori
immunopatholog
effect
pulmonari
eosinophil
infiltr
antibodi
ab
mediat
diseas
enhanc
follow
subsequ
viral
challeng
vaccin
anim
recent
also
show
whole
inactiv
merscov
vaccin
wiv
associ
significantli
increas
pulmonari
eosinophil
infiltr
accompani
elev
level
cytokin
vaccin
human
transgen
tg
mice
respons
viru
challeng
given
previou
observ
merscov
vaccin
base
fulllength
protein
could
pose
potenti
safeti
concern
similar
associ
sarscov
vaccin
neutral
epitoperich
region
could
consid
altern
target
effect
safe
mer
vaccin
protect
could
clearli
enhanc
appropri
immunolog
modul
ligand
type
ii
membran
protein
key
costimulatori
molecul
essenti
regul
immun
system
express
transient
activ
cell
mainli
receptor
constitut
express
antigenpres
cell
apc
repres
crucial
link
innat
adapt
immun
potenti
molecular
adjuv
investig
sever
group
use
multipl
strategi
previous
develop
nonrepl
recombin
adenoviru
vector
prototyp
vaccin
secret
viral
protein
target
apc
use
studi
provid
proof
concept
vaccin
platform
character
enhanc
durabl
breadth
potenc
univers
protect
influenza
virus
differ
mous
model
extend
optim
previou
platform
use
express
secret
fusion
protein
compris
head
globular
ectodomain
merscov
protein
murin
use
trimer
motif
express
fusion
protein
trimer
nonpolar
linker
provid
flexibl
vaccin
subject
systemat
analys
protect
safeti
highli
merscov
permiss
tg
mous
model
fusion
gene
design
codonoptim
express
secret
consensu
merscov
subunit
amino
acid
brief
avail
merscov
sequenc
download
genbank
databas
dataset
filter
remov
sequenc
contain
ambigu
amino
acid
code
bjouxz
final
dataset
multipli
align
use
clustalw
shannon
entropi
posit
determin
consensu
subunit
sequenc
obtain
signal
peptid
merscov
protein
maintain
nterminu
secret
fusion
protein
cell
synthet
fusion
gene
synthes
link
code
region
merscov
histidin
tag
code
sequenc
follow
code
region
fibritin
trimer
motif
connect
via
nonpolar
amino
acid
linker
ectodomain
amino
acid
code
region
express
fusion
protein
fusion
gene
use
gener
propos
construct
addit
vaccin
express
secret
consensu
protein
alon
vector
control
express
green
fluoresc
protein
shown
figur
vero
cell
cultur
maintain
complet
dulbecco
modifi
eagl
medium
dmem
supplement
heatinactiv
fetal
bovin
serum
provid
heinz
feldmann
nation
institut
poli
p
f
tag
l
poli
p
poli
p
gfp
figur
schemat
represent
middl
east
respiratori
syndrom
coronaviru
vaccin
candid
propos
recombin
adenoviru
construct
engin
express
fusion
protein
subunit
contain
protein
signal
peptid
ntermin
follow
trimer
motif
deriv
bacteriophag
fibritin
f
fuse
ectodomain
murin
ligand
cterminu
thu
express
trimer
fusion
protein
via
f
construct
place
control
cytomegaloviru
promot
cmv
front
bovin
growth
hormonepoli
site
poli
control
construct
includ
control
vector
express
green
fluoresc
protein
assay
previous
describ
work
involv
infecti
merscov
conduct
within
approv
biosafeti
level
galveston
nation
laboratori
gnl
univers
texa
medic
branch
utmb
galveston
immunogen
protect
efficaci
vaccin
candid
evalu
merscov
infect
tg
mous
model
total
tg
mice
age
month
use
micegroup
mice
intramuscularli
immun
twice
day
apart
vaccin
candid
figur
blood
sampl
collect
week
immun
via
retroorbit
bleed
four
week
second
immun
mice
intranas
challeng
tcid
median
lethal
dose
ld
merscov
day
postinfect
mice
group
kill
assess
viru
titer
lung
patholog
remain
mice
monitor
morbid
mortal
daili
basi
day
anim
studi
involv
infecti
merscov
conduct
within
approv
anim
laboratori
gnl
accord
guid
care
use
laboratori
anim
nih
associ
assess
accredit
laboratori
anim
care
institut
anim
protocol
approv
utmb
anim
hous
onsit
anim
facil
light
dark
cycl
room
temperatur
humid
kept
respect
ad
libitum
access
food
water
day
challeng
mice
group
euthan
lung
collect
examin
patholog
chang
immun
viral
challeng
brief
lung
tissu
fix
buffer
formalin
hour
transfer
ethanol
later
paraffin
embed
histopatholog
evalu
perform
deparaffin
section
stain
routin
hematoxylin
eosin
stain
evalu
histopatholog
done
pathologist
blind
specimen
sourc
numer
score
assign
assess
extent
patholog
damag
follow
observ
patholog
undetect
infiltr
mild
patholog
infiltr
moder
patholog
infiltr
sever
patholog
infiltr
lung
collect
challeng
mice
day
postchalleng
use
determin
viral
titer
tcid
brief
piec
collect
lung
tissu
weigh
homogen
phosphatebuff
salin
contain
fetal
calf
serum
tissuelys
qiagen
clarif
cellular
tissu
debri
centrifug
titer
infecti
viru
suspens
infect
tissu
determin
use
tcid
assay
viru
titer
individu
sampl
express
log
tcid
per
gram
tissu
minim
detect
level
viru
log
tcid
determin
lung
size
lung
sampl
group
mice
n
per
group
transfer
individu
vial
contain
rnalat
solut
subsequ
homogen
subject
total
rna
isol
use
trizol
reagent
determin
viral
titer
lung
merscovspecif
upstream
e
gene
upe
endogen
control
gene
mous
quantifi
use
reversetranscript
quantit
polymeras
chain
reaction
rtqpcr
monitor
morbid
mortal
upe
mrna
express
valu
calcul
replic
express
equival
log
equival
per
gram
tcid
eqg
tissu
standard
ct
method
use
biorad
cfx
manag
softwar
endpoint
titer
total
immunoglobulin
g
igg
well
isotyp
includ
immun
mice
determin
enzymelink
immunosorb
assay
describ
previous
serum
sampl
test
serial
dilut
start
endpoint
titer
determin
express
reciproc
highest
dilut
gave
optic
densiti
signal
higher
cutoff
valu
defin
mean
preble
sampl
plu
standard
deviat
sd
merspseudotyp
viral
particl
merspp
produc
titrat
use
cell
line
describ
previous
plasmid
gener
merspp
kindli
provid
dr
nigel
temperton
univers
kent
unit
kingdom
heatinactiv
serum
sampl
prepar
serial
dilut
start
test
duplic
nunc
white
plate
standard
amount
merspp
rel
light
unit
ad
well
plate
incub
hour
approxim
cell
ad
well
incub
hour
cell
cell
merspp
includ
quadrupl
control
plate
follow
incub
cell
lyse
luciferas
activ
develop
measur
use
brightglo
luciferas
assay
system
promega
accord
manufactur
instruct
log
median
inhibitori
concentr
ic
neutral
titer
calcul
serum
sampl
use
graphpad
prism
softwar
standard
live
viru
microneutr
mn
assay
use
previous
describ
brief
start
dilut
volum
serial
dilut
heatinactiv
sera
mix
equal
volum
media
contain
tcid
merscov
dilut
test
duplic
plate
antibodyviru
mixtur
incub
hour
transfer
confluent
vero
cell
monolay
plate
vero
cell
cultur
dmem
medium
without
viru
includ
posit
neg
control
respect
hour
incub
nab
titer
serum
sampl
determin
reciproc
highest
dilut
capabl
complet
prevent
virusinduc
cytopath
effect
well
mn
statist
analysi
conduct
use
analysi
varianc
bonferroni
posttest
adjust
multipl
comparison
group
use
graphpad
prism
softwar
evalu
immunogen
gener
vectorbas
mer
vaccin
immun
mice
intramuscularli
dose
individu
vaccin
measur
level
circul
igg
isotyp
week
immun
observ
induc
ab
isotyp
tg
mice
primari
secondari
immun
figur
expect
control
vector
fail
elicit
ab
respons
notabl
singl
dose
dose
consist
elicit
significantli
higher
level
total
igg
well
isotyp
compar
control
group
immun
figur
wherea
immun
singl
dose
induc
signific
titer
total
igg
compar
control
group
second
dose
eventu
induc
significantli
higher
level
compar
control
group
interestingli
immun
mice
second
dose
enhanc
level
circulatori
igg
test
isotyp
compar
group
furthermor
dose
enhanc
significantli
compar
dose
mean
ratio
sd
sd
prime
boost
respect
contrast
boost
second
dose
result
signific
increas
total
igg
particularli
isotyp
compar
singl
dose
suggest
bia
toward
respons
demonstr
mean
ratio
sd
sd
prime
boost
respect
togeth
data
show
target
secret
apc
via
enhanc
igg
ab
level
also
boost
respons
demonstr
markedli
elev
titer
antibodi
especi
boost
extend
analysi
evalu
effector
function
induc
ab
measur
neutral
activ
immun
expect
immun
mice
group
show
detect
level
nab
sampl
collect
immun
shown
figur
singl
dose
either
elicit
high
level
nab
compar
control
group
consist
capabl
induc
significantli
higher
level
nab
live
pseudotyp
merscov
viru
suggest
better
vaccin
promot
strong
humor
respons
neutral
activ
merscov
howev
boost
anim
elicit
robust
signific
level
nab
indic
least
dose
requir
induc
nab
level
similar
obtain
singl
dose
find
clearli
confirm
incorpor
molecular
adjuv
could
effect
enhanc
immunogen
vaccin
may
repres
promis
vaccin
platform
induc
protect
immun
singl
dose
demonstr
vaccin
superior
elicit
immun
respons
tg
mice
next
investig
vaccin
could
effect
protect
highli
merscov
permiss
mice
viral
challeng
end
vaccin
mice
challeng
ld
merscov
subsequ
monitor
week
clear
mice
immun
twice
either
complet
protect
base
clinic
sign
diseas
weight
loss
mortal
figur
wherea
anim
expectedli
succumb
lethal
infect
within
day
like
due
enceph
find
suggest
vaccin
protect
mous
model
confirm
immun
tg
mice
protect
merscov
infect
challeng
measur
lung
viral
titer
infecti
progeni
viru
viral
rna
day
postchalleng
vero
infect
assay
rtqpcr
respect
analysi
infecti
viral
titer
reveal
immun
vaccin
significantli
protect
viral
replic
undetect
level
compar
challeng
mice
figur
result
confirm
averag
reduct
pulmonari
viral
rna
compar
group
figur
mention
albeit
statist
signific
anim
viral
rna
load
lower
log
compar
group
consist
overal
stronger
immun
respons
observ
group
final
investig
carri
assess
safeti
vaccin
candid
rule
vaccineassoci
pulmonari
injuri
observ
vaccin
coronavirus
evalu
lung
patholog
immun
challeng
mice
show
multipl
monocyt
lymphocyt
infiltr
moder
patholog
lung
group
day
postchalleng
compar
group
show
minim
inflammatori
infiltr
figur
surprisingli
although
immun
protect
anim
death
weight
loss
prevent
lung
infiltr
similar
observ
perivascular
hemorrhag
whole
lung
examin
mice
immun
vaccin
figur
togeth
result
suggest
although
alon
could
protect
anim
viral
infect
may
inadvert
induc
lung
patholog
use
target
molecul
molecular
adjuv
enhanc
immunogen
protect
efficaci
also
prevent
vaccineassoci
pulmonari
patholog
rapid
spread
persist
merscov
arabian
peninsula
addit
associ
high
mortal
rate
repres
seriou
global
public
health
concern
particularli
elimin
zoonot
reservoir
extrem
unlik
current
set
threat
complic
absenc
prophylact
therapeut
measur
therefor
develop
effect
safe
vaccin
urgent
need
prevent
contain
merscov
sever
group
investig
variou
merscov
vaccin
platform
sever
anim
model
howev
seriou
safeti
concern
associ
vaccin
sever
coronavirus
includ
merscov
need
elucid
better
understood
show
studi
although
express
capabl
induc
signific
level
igg
nab
specif
merscov
immun
mice
incorpor
substanti
enhanc
immunogen
demonstr
effect
singl
immun
dose
suffici
elicit
stronger
robust
immun
respons
compar
control
group
consist
previou
report
importantli
vaccin
provid
complet
protect
prevent
viru
replic
significantli
prevent
monocyt
lymphocyt
lung
infiltr
compar
control
group
howev
vaccin
uniformli
induc
vari
degre
sever
perivascular
hemorrhag
within
lung
examin
mice
follow
viral
challeng
regardless
exhibit
full
protect
lethal
merscov
challeng
data
suggest
might
yet
explain
lung
patholog
associ
vectorandor
merscov
vaccin
result
clearli
show
includ
fusion
protein
merscov
vaccin
could
prevent
least
mitig
safeti
concern
undesir
immunopatholog
afford
complet
protect
tg
mice
least
group
develop
differ
radvector
merscov
vaccin
howev
studi
mainli
focus
immunogen
andor
protect
efficaci
may
overlook
possibl
vaccineassoci
patholog
especi
viral
challeng
find
immun
anim
complet
protect
despit
observ
patholog
reminisc
immunopatholog
document
use
wiv
merscov
sarscov
respiratori
syncyti
viru
viral
challeng
note
lung
patholog
also
observ
previou
studi
involv
rhesu
macaqu
immun
high
dose
dna
vaccin
express
merscov
protein
well
mous
model
vaccin
rbd
vector
vaccin
encod
protein
nevertheless
first
report
vaccineassoci
sever
pulmonari
perivascular
hemorrhag
viral
challeng
although
exact
molecular
mechan
underli
vaccineinduc
pulmonari
injuri
associ
vaccin
remain
determin
sever
factor
could
involv
specif
like
higher
level
residu
infecti
virus
mice
detect
rtqpcr
quantit
perhap
qualit
differ
specif
antibodi
tcell
respons
evidenc
lower
level
found
group
could
play
role
pulmonari
viral
load
viral
load
determin
lung
immun
challeng
mice
middl
east
respiratori
syndrom
coronaviru
merscov
viral
load
determin
median
tissu
cultur
infecti
dose
per
gram
tcid
g
tcid
equival
per
gram
tcid
eqg
tcid
reversetranscript
quantit
polymeras
chain
reaction
rtqpcr
assay
respect
limit
detect
tcid
assay
log
dash
line
tcid
eqg
determin
use
standard
curv
gener
dilut
rna
merscov
known
viru
titer
titer
shown
mean
standard
deviat
mice
per
group
experi
p
analysi
varianc
bonferroni
posttest
ns
signific
see
figur
legend
explan
recombin
adenoviru
construct
therefor
futur
studi
includ
systemat
analys
tcell
respons
previous
conduct
fulli
explor
mechan
immunizationinduc
hemorrhag
lung
collect
previou
data
along
report
indic
viral
compon
ie
within
protein
could
involv
inadvert
advers
reaction
similar
associ
differ
sbase
sar
vaccin
studi
suggest
although
could
potenti
vaccin
candid
might
associ
sever
lung
patholog
upon
viral
challeng
infect
find
great
import
order
develop
safe
effect
human
merscov
vaccin
moreov
huge
gap
understand
correl
protect
camel
wane
natur
nab
anim
might
hinder
one
health
approach
tackl
mer
epidem
therefor
critic
better
understand
elucid
safeti
concern
might
associ
merscov
vaccin
develop
safe
effect
human
vaccin
previou
studi
mainli
focus
develop
candid
univers
influenza
vaccin
use
vector
vaccin
target
antigen
cell
via
platform
modifi
optim
util
gener
immunogen
protect
safe
merscov
vaccin
base
subunit
merscov
protein
thu
repres
promis
platform
vaccin
develop
broad
rang
pathogen
